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COPD patients”Dear Editor (Respiratory Medicine)
We greatly appreciate Dr Young’s interest in our publication
and his comments. He points out three important issues
about targeting patients with mild to moderate COPD for
lung cancer screening [1]: the number of patients needed
to screen, the “absence” of overdiagnosis, and the impor-
tance of incorporating spirometry into lung cancer
screening programs.
As he mentions, the lung cancer detection rate in our
cohort was 3.8 fold greater than in the National Lung
Screening Trial (NLST) [2] and similar to that seen in the
Pittsburg Lung Screening Study (PluSS) [3]. If these numbers
are confirmed by other groups we could significantly
decrease the number of patients needed to screen (NNS) by
more than 70%. Incorporating COPD into the selection
criteria for high-risk patients could improve the risk-benefit
ratio of lung cancer screening programs. The apparent
“absence” of overdiagnosis is another important issue
raised by Dr Young. Based on existing data [4], we believe
that the proposed “remodeling/repair microclimate” [5]
favors the development and progression of lung cancer in
COPD patients. It may also favor the development of more
aggressive tumors in this population, thus reducing the
proportion of overdiagnosis in comparison to a population
of healthy smokers [6]. Lastly, but perhaps more impor-
tantly, we agree with Dr Young’s assertion that lung cancer
screening programs should incorporate spirometry even
considering we are screening asymptomatic current and
former smokers. Such a program may be the ideal setting to
tackle two of the most prevalent and deadly tobacco
associated diseases: COPD and lung cancer. Underdiagnosis
of COPD of around 70e80% is a consistent finding in all
population-based studies performed around the world
[7,8]. Adding spirometry will not only help identificatyDOI of original article: http://dx.doi.org/10.1016/
j.rmed.2013.06.022.
0954-6111/$ - see front matter ª 2014 Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.rmed.2014.01.011individuals with higher risk for lung cancer, but will also
help detect COPD in its early stages when interventions like
smoking cessation may have a greater impact on outcomes.
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